Gavin Giovannoni

Queen Mary University of London — United Kingdom

Medicine · Health Sciences

30h-index5.1kcitations87works2.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Sclerosis Research Studies(69), Polyomavirus and related diseases(20), Immunotherapy and Immune Responses(17), Rheumatoid Arthritis Research and Therapies(16), Peripheral Neuropathies and Disorders(11)

Publications87 total

Neurofilament heavy chain in secondary progressive multiple sclerosis
Multiple Sclerosis Journal·2025· 3 citedOpen Access
Epstein-Barr Virus as a Therapeutic and Preventive Target in Multiple Sclerosis
Current Treatment Options in Neurology·2025· 1 cited
018  Disease control beyond NEDA: the value of non-clinical measures to determine treatment response to natalizumab
Journal of Neurology Neurosurgery & Psychiatry·2022
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years
Multiple Sclerosis Journal·2022· 44 citedOpen Access
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial
Multiple Sclerosis Journal·2022· 32 citedOpen Access
Réduction à long terme du taux de poussées et de progression du handicap confirmée à 48 semaines (CDP48) après 6,5 ans de traitement par ocrelizumab (OCR) chez des patients atteints de sclérose en plaques récurrente (SEP-R)
Revue Neurologique·2021
Sécurité et efficacité chez les patients traités par le diméthyl fumarate et suivis pendant 13 ans : résultats finaux d’ENDORSE
Revue Neurologique·2021
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIG<i>MS</i> study
Multiple Sclerosis Journal·2020· 11 citedOpen Access
Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study
Journal of Neurology·2020· 11 citedOpen Access
Change in cognitive processing speed is associated with cortical grey matter and thalamic volume loss in patients with relapsing-remitting multiple sclerosis (1905)
Neurology·2020· 1 cited
Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIG<i>MS</i>study
Journal of Neurology Neurosurgery & Psychiatry·2020· 44 citedOpen Access
060 Association of brain volume loss and neda outcomes in patients with relapsing multiple sclerosis in the opera i and opera ii studies (ENCORE)
Journal of Neurology Neurosurgery & Psychiatry·2018
PO114 Neda achievement by time interval with daclizumab
Journal of Neurology Neurosurgery & Psychiatry·2017
Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE
Multiple Sclerosis Journal·2017· 3 citedOpen Access
Alemtuzumab CARE-MS I 5-year follow-up
Neurology·2017· 222 citedOpen Access
Alemtuzumab CARE-MS II 5-year follow-up
Neurology·2017· 273 citedOpen Access
Alemtuzumab CARE-MS II 5-year follow-up
Apollo (University of Cambridge)·2017· 7 citedOpen Access
Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis
Multiple Sclerosis and Related Disorders·2017· 9 cited
Effect of delayed‐release dimethyl fumarate on no evidence of disease activity in relapsing–remitting multiple sclerosis: integrated analysis of the phase<scp>III DEFINE</scp>and<scp>CONFIRM</scp>studies
European Journal of Neurology·2017· 58 citedOpen Access
No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study
Multiple Sclerosis Journal·2016· 21 cited
page 1 of 5Next →

Frequent Co-authors

Eva Havrdová(34), Krzysztof Selmaj(25), Douglas L. Arnold(21), Ludwig Kappos(17), Ralf Gold(17), Alasdair Coles(13), Michael Panzara(13), David Margolin(12), J. Theodore Phillips(12), Michael Hutchinson(9), Christian Confavreux(8), Vesna Brinar(8), M. Stojanovic(8), Stephen Lake(8), D. A. S. Compston(8), Fred Lublin(8), A Wajgt(8), Frances Lynn(8), Jacob Elkins(8), Amit Bar‐Or(8)